Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7838098> ?p ?o }
Showing triples 1 to 39 of
39
with 100 triples per page.
- Q7838098 subject Q8760074.
- Q7838098 abstract "Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human monoclonal antibody against CTLA-4, produced by Pfizer, undergoing human trials for the treatment of cancer. Tremelimumab stimulates patients’ immune systems to attack their tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells. This is immune checkpoint blockade.".
- Q7838098 atcPrefix "none".
- Q7838098 casNumber "745013-59-6".
- Q7838098 fdaUniiCode "QEN1X95CIX".
- Q7838098 wikiPageWikiLink Q1047791.
- Q7838098 wikiPageWikiLink Q1335294.
- Q7838098 wikiPageWikiLink Q1427096.
- Q7838098 wikiPageWikiLink Q14875744.
- Q7838098 wikiPageWikiLink Q14907505.
- Q7838098 wikiPageWikiLink Q14907527.
- Q7838098 wikiPageWikiLink Q180614.
- Q7838098 wikiPageWikiLink Q181257.
- Q7838098 wikiPageWikiLink Q193529.
- Q7838098 wikiPageWikiLink Q2012719.
- Q7838098 wikiPageWikiLink Q206921.
- Q7838098 wikiPageWikiLink Q20970073.
- Q7838098 wikiPageWikiLink Q2145898.
- Q7838098 wikiPageWikiLink Q21686041.
- Q7838098 wikiPageWikiLink Q2459042.
- Q7838098 wikiPageWikiLink Q266423.
- Q7838098 wikiPageWikiLink Q30612.
- Q7838098 wikiPageWikiLink Q376266.
- Q7838098 wikiPageWikiLink Q422248.
- Q7838098 wikiPageWikiLink Q483261.
- Q7838098 wikiPageWikiLink Q504775.
- Q7838098 wikiPageWikiLink Q6805152.
- Q7838098 wikiPageWikiLink Q7838098.
- Q7838098 wikiPageWikiLink Q8760074.
- Q7838098 atcPrefix "none".
- Q7838098 casNumber "745013".
- Q7838098 unii "QEN1X95CIX".
- Q7838098 type ChemicalSubstance.
- Q7838098 type Drug.
- Q7838098 type ChemicalObject.
- Q7838098 type Thing.
- Q7838098 type Q8386.
- Q7838098 comment "Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human monoclonal antibody against CTLA-4, produced by Pfizer, undergoing human trials for the treatment of cancer. Tremelimumab stimulates patients’ immune systems to attack their tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction.".
- Q7838098 label "Tremelimumab".